ADVANCE_2020 Phase II Studie zu Atezolizumab und Derazantinib bei Gallengangskarzinom (Aktiv)
AMGEN T-VEC_Atezolizumab The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases. (Aktiv)
GAIN Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (GAIN) (Aktiv)
IMMUWHY (AIO-HEP-0119/ass) A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care (Aktiv)
Immunib Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (Aktiv)
NFAT Validierung der expressionsanalyse nfat-regulierter Gene (Aktiv)
NIFE Nal-IRI, 5-Fluorouracil und Leucovorin versus Gemcitabin plus Cisplatin bei fortgeschrittenem Gallenwegskarzinom (Aktiv)
Erstlinie
DEMAND Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (Aktiv)
HERACLES Hepatocellular carcinoma stereotactic Radiotherapy Clinical Evaluation Study (Aktiv)
IMMUWIN (AIO-HEP-0319/ass) Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit entweder Y-90 SIRT oder TACE bei Patienten mit Leberzellkarzinom im Zwischenstadium mit einem „Pick-the-Winner“ Design - IMMUWIN (Aktiv)
Incyte FIGHT-302 A Phase 3. Open-Label, Randomized, Active-Controlled, Multiicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine plus Cisplatin Chemotherapy in First-Line Treatment of Participants with unresectable or metastatix Cholangiocarcinoma with FGFR2 Rearrangement (Aktiv)
PROMETHEUS-01 Evaluating the treatment of patients with hepatocellular carcinoma (Aktiv)
PROOF Eine multizentrische, offene, randomisierte, kontrollierte Phase 3 Studie mit oRal verabreichtem Infigratinib im Vergleich zu Gemcitabin mit Cisplatin bei Patienten mit fortgeschrittenem/metastasierendem oder inOperablem GallengangskarzinOm mit FGFR2-Genfusionen/Translokationen: Die PROOF -Studie (Aktiv)
WO41535 A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (Aktiv)
Zweitlinie oder später
ACTICCA-1 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Resection of Biliary Tract Cancer (Aktiv)
AIO-HEP-0121/ass - SOLARIS Kombinierte Therapie mit Pembrolizumab und Lenvatinib bei Patienten mit fortgeschrittenem Leberzellkrebs, die unter einer vorherigen Therapie mit Atezolizumab und Bevacizumab ein Fortschreiten ihrer Erkrankung erlitten haben Eine offene Phase-II-Studie mit Pembrolizumab und Lenvatinib bei Patienten mit fortgeschrittenem hepatozellulärem Karzinom, die refraktär auf eine Therapie mit Atezolizumab und Bevacizumab / IO sind - SOLARIS (Aktiv)
AURORA Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) after treatment failure of, or intolerabiliy to first line treatment. (Aktiv)
BI 1403-0011 - BRIGHTLINE-2 Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)
CBGJ398X2204 This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with FGFR genetic alterations. (Aktiv)
CaPture Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (Aktiv)
CaboRISE Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis (Aktiv)
IRIBIL FOLFIRI versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (Aktiv)
KEYNOTE-937 A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
PHITT Paediatric Hepatic International Tumour Trial (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)